COMMUNIQUÉS West-GlobeNewswire

Healthy Gut Announces Updated Holozyme Formula Addressing Digestive Sensitivity to Fructan-Containing Foods
12/01/2026
Boulder, CO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Healthy Gut, a Boulder-based digestive health company, announced the release of an updated formulation of its Holozyme product, reflecting the company’s expanded focus on [...]
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
12/01/2026
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effect The company [...]
argenx Highlights 2026 Strategic Priorities
12/01/2026
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on [...]
Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America
12/01/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North [...]
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
12/01/2026
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, [...]
Publication relative à une notification de transparence
12/01/2026
INFORMATION RÉGLEMENTÉE Publication relative à une notification de transparence Mont-Saint-Guibert (Belgique), le 12 janvier 2026 , 7:00h CET / 1:00h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Publication relating to transparency notification
12/01/2026
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the [...]
Communiqué de presse : Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2
12/01/2026
Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2 Approbation basée sur l’étude de phase 2 TN-10 qui a démontré un retard significatif dans l’apparition du DT1 de stade 3 [...]
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
12/01/2026
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patients Teizeild [...]
Paul Chua Joins Health-ISAC® as Asia Pacific Operations Director
12/01/2026
Chua will spearhead Health-ISAC’s expansion into the APAC region, enhancing cybersecurity and resilience in the global health sector SINGAPORE, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis [...]
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
12/01/2026
White Oak, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control ( [...]
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
11/01/2026
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase [...]
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
11/01/2026
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over [...]
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
11/01/2026
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and [...]
HealthEx Partners with Anthropic to Turn Patients’ Scattered Medical Records into Actionable Health Insights
11/01/2026
HealthEx is the first consumer health record integration for Claude by Anthropic to securely link comprehensive medical histories with user privacy and control SAN FRANCISCO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- JP Morgan [...]
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
11/01/2026
– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale [...]
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
11/01/2026
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV-‘408 is currently [...]
Zymeworks Outlines Strategic Priorities and Outlook for 2026
12/01/2026
Positive Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI Up to $440.0 million in milestone payments [...]
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
12/01/2026
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, [...]

Pages